The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
VJVirtual | AML: the benefit of haploidentical donors
Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, discusses the difficulties in optimizing stem cell donor sources for the treatment of acute myeloid leukemia via transplantation. Specifically, Prof. Mohty discusses the benefit of haploidentical transplantation, especially in light of the challenges COVID-19 is raising. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
